Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience

Background/Aims: Gastric neuroendocrine tumors (G-NETs) are rare tumors, but their incidence is gradually increasing. Despite the existence of many classification systems, determining prognosis and planning treatment in patients with G-NETs remains a clinical challenge. In this study, the prognostic...

Full description

Saved in:
Bibliographic Details
Published in:The Turkish journal of gastroenterology 2020-02, Vol.31 (2), p.91-98
Main Authors: Karakas, Yusuf, Lacin, Sahin, Kurtulan, Olcay, Esin, Ece, Sunar, Veli, Sokmensuer, Cenk, Kilickap, Saadettin, Yalcin, Suayib
Format: Article
Language:English
Subjects:
Cancer
Medical research
Medicine, Experimental
Original
Public health
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c524t-ed16dac74f102b5f7334303ea996fafea4584c59be06c4debe5e0704c467b5b43
cites
container_end_page 98
container_issue 2
container_start_page 91
container_title The Turkish journal of gastroenterology
container_volume 31
creator Karakas, Yusuf
Lacin, Sahin
Kurtulan, Olcay
Esin, Ece
Sunar, Veli
Sokmensuer, Cenk
Kilickap, Saadettin
Yalcin, Suayib
description Background/Aims: Gastric neuroendocrine tumors (G-NETs) are rare tumors, but their incidence is gradually increasing. Despite the existence of many classification systems, determining prognosis and planning treatment in patients with G-NETs remains a clinical challenge. In this study, the prognostic value of the World Health Organization (WHO) 2017 grading system and the effect of surgery on survival in low grade neuroendocrine tumors were investigated. Materials and Methods: G-NETs who were diagnosed between January 2000 and May 2017 were included in the study. Patients' demographic characteristics, treatment details, and survival data were obtained from medical charts. Pathological samples were re-classified according to the WHO 2017 grading system. Results: Of the total 94 evaluated patients, 50 (53.2%) were classified with G1 NETs, 37(39.4%) with G2 NETs, 4(4.2%) with well-differentiated G3 NETs, and the remaining 3 patients with poorly differentiated G3 neuroendocrine carcinoma (NEC). The median follow-up time was 83.2 months. There was a statistically significant difference in 5-year progression free survival (PFS) between G1 tumors (100%) and G2 tumors (76%) (p
doi_str_mv 10.5152/tjg.2020.18919
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7062132</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A623445159</galeid><sourcerecordid>A623445159</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-ed16dac74f102b5f7334303ea996fafea4584c59be06c4debe5e0704c467b5b43</originalsourceid><addsrcrecordid>eNptkkuLFDEURoMoTju6dR1w46baPOvhQhgadYSBEVRchlTqpjpDKmmT1OD4E_zVpu1BEIYsbnJzcriQD6GXlGwllexNuZm3jDCypf1Ah0dow6joG9mS7jHaUE5IIwbRn6FnOd8QwnvasqfojFeK1v0G_f6c4hxiLs7gW-1XwNHisgfMCO3w95j8hC9B-7LH12nWwf3SxcWAd17n7Kwzp-OXu1xgwTYmPOtcUrUFWFOEMEWTXABc1iWm_BZf4OzC7KExEAokDD8PkBwEA8_RE6t9hhf39Rx9-_D-6-6yubr--Gl3cdUYyURpYKLtpE0nLCVslLbjXHDCQQ9Da7UFLWQvjBxGIK0RE4wggXREGNF2oxwFP0fvTt7DOi4wHedI2qtDcotOdypqp_6_CW6v5nirOtIyylkVvL4XpPhjhVzU4rIB73WAuGbFeCc4Z0z2FX11QmftQblgYzWaI64uWsaFqJ84VGr7AFXXBIszMYB1tf_QA5Nizgnsv-kpUcdcqJoLdcyF-psL_gcyoqxe</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2374332258</pqid></control><display><type>article</type><title>Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience</title><source>PubMed (Medline)</source><creator>Karakas, Yusuf ; Lacin, Sahin ; Kurtulan, Olcay ; Esin, Ece ; Sunar, Veli ; Sokmensuer, Cenk ; Kilickap, Saadettin ; Yalcin, Suayib</creator><creatorcontrib>Karakas, Yusuf ; Lacin, Sahin ; Kurtulan, Olcay ; Esin, Ece ; Sunar, Veli ; Sokmensuer, Cenk ; Kilickap, Saadettin ; Yalcin, Suayib ; Department of Pathology, Hacettepe University School of Medicine, Ankara, Turkey ; Zekai Tahir Burak Woman’s Health Research and Training Hospital, Ankara, Turkey ; Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey ; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey ; Clinic of Medical Oncology, Hakkari State Hospital, Hakkari, Turkey ; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey</creatorcontrib><description>Background/Aims: Gastric neuroendocrine tumors (G-NETs) are rare tumors, but their incidence is gradually increasing. Despite the existence of many classification systems, determining prognosis and planning treatment in patients with G-NETs remains a clinical challenge. In this study, the prognostic value of the World Health Organization (WHO) 2017 grading system and the effect of surgery on survival in low grade neuroendocrine tumors were investigated. Materials and Methods: G-NETs who were diagnosed between January 2000 and May 2017 were included in the study. Patients' demographic characteristics, treatment details, and survival data were obtained from medical charts. Pathological samples were re-classified according to the WHO 2017 grading system. Results: Of the total 94 evaluated patients, 50 (53.2%) were classified with G1 NETs, 37(39.4%) with G2 NETs, 4(4.2%) with well-differentiated G3 NETs, and the remaining 3 patients with poorly differentiated G3 neuroendocrine carcinoma (NEC). The median follow-up time was 83.2 months. There was a statistically significant difference in 5-year progression free survival (PFS) between G1 tumors (100%) and G2 tumors (76%) (p&lt;0.001). However, there was no statistically significant deference in 5-year overall survival rate (OS) for G1 (97%) and G2 (82%) tumors (p=0.141). When G2 and G1 NETs were compared according to their surgical approach, radical surgery was more frequently performed in patients with G2 tumors (p&lt;0.001). However, radical surgery did not improve PFS in G1 and G2 NETs. Conclusion: The WHO 2017 NET classification system may have low prognostic value for determining the prognosis of patients with G1 and G2 tumors. Radical surgery for G1 and G2 NETs did not improve PFS in our study. Keywords: Gastric neuroendocrine tumors, WHO 2017 neuroendocrine tumor classification, prognosis, grade</description><identifier>ISSN: 1300-4948</identifier><identifier>EISSN: 2148-5607</identifier><identifier>DOI: 10.5152/tjg.2020.18919</identifier><identifier>PMID: 32141816</identifier><language>eng</language><publisher>AVES</publisher><subject>Cancer ; Medical research ; Medicine, Experimental ; Original ; Public health</subject><ispartof>The Turkish journal of gastroenterology, 2020-02, Vol.31 (2), p.91-98</ispartof><rights>COPYRIGHT 2020 AVES</rights><rights>Copyright 2020 by Turkish Society of Gastroenterology 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-ed16dac74f102b5f7334303ea996fafea4584c59be06c4debe5e0704c467b5b43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062132/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062132/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Karakas, Yusuf</creatorcontrib><creatorcontrib>Lacin, Sahin</creatorcontrib><creatorcontrib>Kurtulan, Olcay</creatorcontrib><creatorcontrib>Esin, Ece</creatorcontrib><creatorcontrib>Sunar, Veli</creatorcontrib><creatorcontrib>Sokmensuer, Cenk</creatorcontrib><creatorcontrib>Kilickap, Saadettin</creatorcontrib><creatorcontrib>Yalcin, Suayib</creatorcontrib><creatorcontrib>Department of Pathology, Hacettepe University School of Medicine, Ankara, Turkey</creatorcontrib><creatorcontrib>Zekai Tahir Burak Woman’s Health Research and Training Hospital, Ankara, Turkey</creatorcontrib><creatorcontrib>Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey</creatorcontrib><creatorcontrib>Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey</creatorcontrib><creatorcontrib>Clinic of Medical Oncology, Hakkari State Hospital, Hakkari, Turkey</creatorcontrib><creatorcontrib>Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey</creatorcontrib><title>Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience</title><title>The Turkish journal of gastroenterology</title><description>Background/Aims: Gastric neuroendocrine tumors (G-NETs) are rare tumors, but their incidence is gradually increasing. Despite the existence of many classification systems, determining prognosis and planning treatment in patients with G-NETs remains a clinical challenge. In this study, the prognostic value of the World Health Organization (WHO) 2017 grading system and the effect of surgery on survival in low grade neuroendocrine tumors were investigated. Materials and Methods: G-NETs who were diagnosed between January 2000 and May 2017 were included in the study. Patients' demographic characteristics, treatment details, and survival data were obtained from medical charts. Pathological samples were re-classified according to the WHO 2017 grading system. Results: Of the total 94 evaluated patients, 50 (53.2%) were classified with G1 NETs, 37(39.4%) with G2 NETs, 4(4.2%) with well-differentiated G3 NETs, and the remaining 3 patients with poorly differentiated G3 neuroendocrine carcinoma (NEC). The median follow-up time was 83.2 months. There was a statistically significant difference in 5-year progression free survival (PFS) between G1 tumors (100%) and G2 tumors (76%) (p&lt;0.001). However, there was no statistically significant deference in 5-year overall survival rate (OS) for G1 (97%) and G2 (82%) tumors (p=0.141). When G2 and G1 NETs were compared according to their surgical approach, radical surgery was more frequently performed in patients with G2 tumors (p&lt;0.001). However, radical surgery did not improve PFS in G1 and G2 NETs. Conclusion: The WHO 2017 NET classification system may have low prognostic value for determining the prognosis of patients with G1 and G2 tumors. Radical surgery for G1 and G2 NETs did not improve PFS in our study. Keywords: Gastric neuroendocrine tumors, WHO 2017 neuroendocrine tumor classification, prognosis, grade</description><subject>Cancer</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Original</subject><subject>Public health</subject><issn>1300-4948</issn><issn>2148-5607</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNptkkuLFDEURoMoTju6dR1w46baPOvhQhgadYSBEVRchlTqpjpDKmmT1OD4E_zVpu1BEIYsbnJzcriQD6GXlGwllexNuZm3jDCypf1Ah0dow6joG9mS7jHaUE5IIwbRn6FnOd8QwnvasqfojFeK1v0G_f6c4hxiLs7gW-1XwNHisgfMCO3w95j8hC9B-7LH12nWwf3SxcWAd17n7Kwzp-OXu1xgwTYmPOtcUrUFWFOEMEWTXABc1iWm_BZf4OzC7KExEAokDD8PkBwEA8_RE6t9hhf39Rx9-_D-6-6yubr--Gl3cdUYyURpYKLtpE0nLCVslLbjXHDCQQ9Da7UFLWQvjBxGIK0RE4wggXREGNF2oxwFP0fvTt7DOi4wHedI2qtDcotOdypqp_6_CW6v5nirOtIyylkVvL4XpPhjhVzU4rIB73WAuGbFeCc4Z0z2FX11QmftQblgYzWaI64uWsaFqJ84VGr7AFXXBIszMYB1tf_QA5Nizgnsv-kpUcdcqJoLdcyF-psL_gcyoqxe</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Karakas, Yusuf</creator><creator>Lacin, Sahin</creator><creator>Kurtulan, Olcay</creator><creator>Esin, Ece</creator><creator>Sunar, Veli</creator><creator>Sokmensuer, Cenk</creator><creator>Kilickap, Saadettin</creator><creator>Yalcin, Suayib</creator><general>AVES</general><general>Turkish Society of Gastroenterology</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200201</creationdate><title>Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience</title><author>Karakas, Yusuf ; Lacin, Sahin ; Kurtulan, Olcay ; Esin, Ece ; Sunar, Veli ; Sokmensuer, Cenk ; Kilickap, Saadettin ; Yalcin, Suayib</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-ed16dac74f102b5f7334303ea996fafea4584c59be06c4debe5e0704c467b5b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Original</topic><topic>Public health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karakas, Yusuf</creatorcontrib><creatorcontrib>Lacin, Sahin</creatorcontrib><creatorcontrib>Kurtulan, Olcay</creatorcontrib><creatorcontrib>Esin, Ece</creatorcontrib><creatorcontrib>Sunar, Veli</creatorcontrib><creatorcontrib>Sokmensuer, Cenk</creatorcontrib><creatorcontrib>Kilickap, Saadettin</creatorcontrib><creatorcontrib>Yalcin, Suayib</creatorcontrib><creatorcontrib>Department of Pathology, Hacettepe University School of Medicine, Ankara, Turkey</creatorcontrib><creatorcontrib>Zekai Tahir Burak Woman’s Health Research and Training Hospital, Ankara, Turkey</creatorcontrib><creatorcontrib>Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey</creatorcontrib><creatorcontrib>Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey</creatorcontrib><creatorcontrib>Clinic of Medical Oncology, Hakkari State Hospital, Hakkari, Turkey</creatorcontrib><creatorcontrib>Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Turkish journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karakas, Yusuf</au><au>Lacin, Sahin</au><au>Kurtulan, Olcay</au><au>Esin, Ece</au><au>Sunar, Veli</au><au>Sokmensuer, Cenk</au><au>Kilickap, Saadettin</au><au>Yalcin, Suayib</au><aucorp>Department of Pathology, Hacettepe University School of Medicine, Ankara, Turkey</aucorp><aucorp>Zekai Tahir Burak Woman’s Health Research and Training Hospital, Ankara, Turkey</aucorp><aucorp>Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey</aucorp><aucorp>Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey</aucorp><aucorp>Clinic of Medical Oncology, Hakkari State Hospital, Hakkari, Turkey</aucorp><aucorp>Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience</atitle><jtitle>The Turkish journal of gastroenterology</jtitle><date>2020-02-01</date><risdate>2020</risdate><volume>31</volume><issue>2</issue><spage>91</spage><epage>98</epage><pages>91-98</pages><issn>1300-4948</issn><eissn>2148-5607</eissn><abstract>Background/Aims: Gastric neuroendocrine tumors (G-NETs) are rare tumors, but their incidence is gradually increasing. Despite the existence of many classification systems, determining prognosis and planning treatment in patients with G-NETs remains a clinical challenge. In this study, the prognostic value of the World Health Organization (WHO) 2017 grading system and the effect of surgery on survival in low grade neuroendocrine tumors were investigated. Materials and Methods: G-NETs who were diagnosed between January 2000 and May 2017 were included in the study. Patients' demographic characteristics, treatment details, and survival data were obtained from medical charts. Pathological samples were re-classified according to the WHO 2017 grading system. Results: Of the total 94 evaluated patients, 50 (53.2%) were classified with G1 NETs, 37(39.4%) with G2 NETs, 4(4.2%) with well-differentiated G3 NETs, and the remaining 3 patients with poorly differentiated G3 neuroendocrine carcinoma (NEC). The median follow-up time was 83.2 months. There was a statistically significant difference in 5-year progression free survival (PFS) between G1 tumors (100%) and G2 tumors (76%) (p&lt;0.001). However, there was no statistically significant deference in 5-year overall survival rate (OS) for G1 (97%) and G2 (82%) tumors (p=0.141). When G2 and G1 NETs were compared according to their surgical approach, radical surgery was more frequently performed in patients with G2 tumors (p&lt;0.001). However, radical surgery did not improve PFS in G1 and G2 NETs. Conclusion: The WHO 2017 NET classification system may have low prognostic value for determining the prognosis of patients with G1 and G2 tumors. Radical surgery for G1 and G2 NETs did not improve PFS in our study. Keywords: Gastric neuroendocrine tumors, WHO 2017 neuroendocrine tumor classification, prognosis, grade</abstract><pub>AVES</pub><pmid>32141816</pmid><doi>10.5152/tjg.2020.18919</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1300-4948
ispartof The Turkish journal of gastroenterology, 2020-02, Vol.31 (2), p.91-98
issn 1300-4948
2148-5607
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7062132
source PubMed (Medline)
subjects Cancer
Medical research
Medicine, Experimental
Original
Public health
title Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A46%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20the%202017%20World%20Health%20Organization%20Classification%20System%20for%20gastric%20neuroendocrine%20tumors:%20A%20single-center%20experience&rft.jtitle=The%20Turkish%20journal%20of%20gastroenterology&rft.au=Karakas,%20Yusuf&rft.aucorp=Department%20of%20Pathology,%20Hacettepe%20University%20School%20of%20Medicine,%20Ankara,%20Turkey&rft.date=2020-02-01&rft.volume=31&rft.issue=2&rft.spage=91&rft.epage=98&rft.pages=91-98&rft.issn=1300-4948&rft.eissn=2148-5607&rft_id=info:doi/10.5152/tjg.2020.18919&rft_dat=%3Cgale_pubme%3EA623445159%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c524t-ed16dac74f102b5f7334303ea996fafea4584c59be06c4debe5e0704c467b5b43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2374332258&rft_id=info:pmid/32141816&rft_galeid=A623445159&rfr_iscdi=true